Biomedical imaging in the postgenomic era: opportunities and challenges

From molecular imaging to systems diagnostics: time for another paradigm shift?

The term "Molecular Imaging" has hit the consciousness of radiologists only in the past decade although many of the concepts that molecular imaging encompasses has been practiced in biomedical imaging, especially in nuclear medicine, for many decades. Many new imaging techniques have allowed us to interrogate biologic events at the cellular and molecular level in vivo in four dimensions but the challenge now is to translate these techniques into clinical practice in a way that will enable us to revolutionize healthcare delivery. The purpose of this article is to introduce the term "Systems Diagnostics" and examine how radiologists can become translators of disparate sources of information into medical decisions and therapeutic actions.

Imaging informatics for personalised medicine: applications and challenges

Imaging informatics has emerged as a major research theme in biomedicine in the last few decades. Currently, personalised, predictive and preventive patient care is believed to be one of the top priorities in biomedical research and practice. Imaging informatics plays a major role in biomedicine studies. This paper reviews main applications and challenges of imaging informatics in biomedicine.

Molecular imaging of hepatocellular carcinoma

Molecular imaging may be defined as spatially localized and/or temporally resolved sensing of molecular and cellular processes in vivo. An imageable molecular event may be the result of the overexpression of a gene that produces a specific messenger RNA. The overexpressed protein could be an enzyme or could be incorporated into cell-surface transporters or receptors. Any step of this process is a potential target for molecular imaging. Current molecular imaging modalities include magnetic resonance imaging, nuclear imaging, ultrasound, and optical imaging. Nuclear medicine has been at the forefront of molecular imaging because of the relatively high sensitivity to detect nanomolar or picomolar quantities of the radiolabeled imaging probe. Imaging has had a central role in the diagnosis of hepatocellular carcinoma (HCC), which is considered the fifth most frequent malignancy worldwide. Nuclear imaging was one of the earlier modalities used for liver imaging. Traditional tracers included technetium 99m ( 99m Tc) sulfur colloid, gallium 67, and 99m Tc iminodiacetate acid analogues. Other less traditional probes include 99m Tc diethylenetriamine pentaacetic acid-galactosyl-human serum albumin for evaluation of functional liver volume and 99m Tc-labeled tetrofosmin and methoxisobutylisonitrile for detecting drug resistance. Fluorodeoxyglucose is the most widely used probe for positron emission tomography (PET) tumor imaging; however, carbon 11-labeled acetate appears to show improved sensitivity and specificity for HCC. Oxygen 15 PET imaging allows for the measurement of hepatic and tumor blood flow. Difficulties developing specific imaging methods for HCC are caused by the lack of obvious specific molecular targets, problems with drug delivery, and poor contrast-to-noise. No magic molecular imaging method exists today to accurately detect, characterize, and monitor HCC in vivo.

Molecular imaging in oncology

Cancer is a genetic disease that manifests in loss of normal cellular homeostatic mechanisms. The biology and therapeutic modulation of neoplasia occurs at the molecular level. An understanding of these molecular processes is therefore required to develop novel prognostic and early biomarkers of response. In addition to clinical applications, increased impetus for the development of such technologies has been catalysed by pharmaceutical companies investing in the development of molecular therapies. The discipline of molecular imaging therefore aims to image these important molecular processes in vivo. Molecular processes, however, operate at short length scales and concentrations typically beyond the resolution of clinical imaging. Solving these issues will be a challenge to imaging research. The successful implementations of molecular imaging in man will only be realised by the close co-operation amongst molecular biologists, chemists and the imaging scientists.

The development and application of functional nuclear magnetic resonance toin vivotherapeutic anticancer research

A little over 30 years ago, Sir Godfrey Hounsfield and his colleagues revolutionized medical imaging by developing CT scanning. In recent years a combination of improved technology and a deeper understanding of tumour biology have led to the development of imaging based strategies aimed at interrogating tissue structure and function. The prospects of this new technology include the prediction of tumour response and the non-invasive study of conventionally inaccessible yet important pharmacological compartments. This article explores how functional nuclear MRI and spectroscopy have been used in predicting response to anticancer therapy in rectal cancers and to assess the biliary excretion of chemotherapeutics.